Abstract
Pareidolias are illusionary phenomena wherein ambiguous forms appear meaningful. In clinical research, pareidolias have been studied using paper or desktop test formats to deconstruct visuo-perceptual mechanisms. Translating this work on to an accessible, scalable setup such as smartphones is currently unknown. Here, we designed a smartphone-based pareidolia test to study visual processes affecting gaze behavior of cognitively healthy individuals using a standard, native front-facing camera. We optimized our system using machine learning and explored the challenges involved in user behavior, demographic specificity, and test functionality. We performed our experiments on 52 healthy Japanese adults, aged between 50 to 80 years who underwent MMSE and the smartphone test for pareidolias. Gaze movements on the 15-min, user-centric evaluation was calibrated to every individual. Results showed test responses with minimal differences with respect to age, sex, and completion time. Personalized calibrations improved the model’s prediction performance and quantification of gaze tracking metrics aligned with that of commercial grade eye-trackers. Our findings demonstrate the applicability and scalability of pareidolia testing on smartphone platforms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NEDO-NEP 2024 grant; by the AMED Medical Device (AMED-SENTAN) grant, Japan, 2023-2024 (Assignment ID: J230705024); and by the KAKENHI Grant-in-Aid for Early-Career Scientists (Grant number 21K15680).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Osaka University institution review board cleared the protocol for the study to be performed in the Department of Neurology, Osaka University, Japan in accordance with the ethical standards of the Declaration of Helsinki (IRB Approval number 22307).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data produced in the present study are available upon reasonable request to the authors
